Merck & Co., Inc. (MRK) operating KPIs
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)
Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%
Merck proQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b
Latest, FY2025
2,451
Period ended Dec 31, 2025
Change on a year earlier
-1.4%
2,485 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2,451 | -1.4% | Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗ |
| FY2024 | Dec 31, 2024 | 2,485 | +4.9% | Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗ |
| FY2023 | Dec 31, 2023 | 2,368 | +5.7% | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2022 | Dec 31, 2022 | 2,241 | +5.0% | Form 10-K (filed 2025-02-25) ↗ |
| FY2021 | Dec 31, 2021 | 2,135 | +13.7% | Form 10-K (filed 2024-02-26) ↗ |
| FY2020 | Dec 31, 2020 | 1,878 | -17.5% | Form 10-K (filed 2023-02-24) ↗ |
| FY2019 | Dec 31, 2019 | 2,275 | +26.5% | Form 10-K (filed 2022-02-25) ↗ |
| FY2018 | Dec 31, 2018 | 1,798 | +7.3% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 1,676 | +2.2% | Form 10-K (filed 2020-02-26) ↗ |
| FY2016 | Dec 31, 2016 | 1,640 | – | Form 10-K (filed 2019-02-27) ↗ |
Breakdown
What makes up proquad / m-m-r ii / varivax (combined pediatric vaccines franchise) — worldwide sales ($m)
- ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — U.S. sales ($M)1,885 · FY2025
- ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — International sales ($M)566 · FY2025
- ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide reported growth YoY (%)-1.0% · FY2025
- ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide constant-currency (ex-exchange) growth YoY (%)-2.0% · FY2025
- Varivax (varicella live virus vaccine) — Worldwide sales ($M)1,041 · FY2025
- ProQuad (measles, mumps, rubella and varicella virus vaccine) — Worldwide sales ($M)930 · FY2025
- M-M-R II (measles, mumps and rubella virus vaccine) — Worldwide sales ($M)480 · FY2025
Cite this data
StockData. (2026). Merck ProQuad / M-M-R II / Varivax (Combined Pediatric Vaccines Franchise) — Worldwide sales ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_proquad_mmr_varivax
See every metric in the Merck KPI table. Data updated Oct 26, 2026.